Treatment of anemia in patients with chronic renal insufficiency with recombinant human erythropoietin

• Published in: Srpski arhiv za celokupno lekarstvo Vol. 124; no. 3-4; p. 93
• Main Authors: Djukanović, Lj, Lezaić, V
• Format: Journal Article
• Language: Serbian
• Published: Serbia 01-03-1996
• Subjects: Anemia - etiology; Anemia - therapy; Erythropoietin - therapeutic use; Humans; Kidney Failure, Chronic - complications; Recombinant Proteins
• ISSN: 0370-8179

The discovery of recombinant human erythropoietin has enabled treatment of anaemia in patients whose anaemia was primarily caused by the lack of erythropoietin. This agent was most widely used in the treatment of anaemia in chronic renal failure patients. Non-regulated hypertension is considered to be the only absolute contraindication for recombinant human erythropoietin application, but thrombocytosis, predisposition to thromboses of arterio-venous fistulae, and convulsions are regarded as relative contraindications. Recombinant human erythropoietin may be administered intravenously, but the subcutaneous route is considered more rational. The treatment is initiated by low doses with gradual dose increase, what enables gradual anaemia correction and prevents the appearance of adverse effects. Haemoglobin level of around 100 g/l is considered the target haemoglobin level. The majority of patients respond well to treatment by human recombinant erythropoietin and the absence of anaemia improvement may be the result of iron deficiency, occult haemorrhages, chronic infection, inadequate dialysis, secondary hyperparathyroidism, aluminium intoxication. Anaemia improvement during the treatment with recombinant erythropoietin leads to the improvement of function of most organs and the quality of life in general as well as avoidance of blood transfusions and their adverse effects. The most frequent adverse effect of recombinant erythropoietin is the development of iron deficiency or hypertension aggravation.